Aoki A, Kay G L, Zubiate P, Ruggio J, Kay J H
Heart Institute, Hospital of the Good Samaritan, Los Angeles.
Chest. 1993 Nov;104(5):1627-9. doi: 10.1378/chest.104.5.1627.
Recently, a new technique for myocardial protection that does not rely on hypothermia has been reported. In this method, the heart is continuously perfused with normothermic hyperkalemic blood cardioplegia during the cross-clamp period. Cardiac arrest is achieved and maintained using high levels of potassium. Hypothermia is not part of this technique; thus, the danger of hypothermia can be avoided in the patient with cold agglutinin disease without compromising myocardial protection. This communication reports our experience using retrograde continuous normothermic blood cardioplegia in one patient with potent cold agglutinins and severe coronary artery occlusive disease. This patient experienced an uneventful operative and postoperative course and remains asymptomatic, now more than two years after operation.
最近，一种不依赖低温的心肌保护新技术已被报道。在这种方法中，在阻断主动脉期间，心脏持续灌注常温高钾血液停搏液。通过高水平的钾实现并维持心脏停搏。低温不是该技术的一部分；因此，在患有冷凝集素病的患者中可以避免低温的危险，而不会影响心肌保护。本报告介绍了我们对一名患有强效冷凝集素和严重冠状动脉闭塞性疾病的患者使用逆行持续常温血液停搏液的经验。该患者手术和术后过程顺利，术后两年多仍无症状。
